Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Deferred Revenue (2018)

Anika Therapeutics (ANIK) has disclosed Current Deferred Revenue for 7 consecutive years, with $52000.0 as the latest value for Q3 2018.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $52000.0 in Q3 2018 year-over-year; TTM through Sep 2018 was $52000.0, a N/A change, with the full-year FY2014 number at $24510.0, down 86.42% from a year prior.
  • Current Deferred Revenue was $52000.0 for Q3 2018 at Anika Therapeutics, down from $74000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $139535.0 in Q1 2015 to a low of $12885.0 in Q3 2014.
  • A 3-year average of $48299.0 and a median of $35938.0 in 2015 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: plummeted 98.99% in 2014, then soared 200.64% in 2015.
  • Anika Therapeutics' Current Deferred Revenue stood at $24510.0 in 2014, then skyrocketed by 38.51% to $33948.0 in 2015, then skyrocketed by 53.18% to $52000.0 in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Current Deferred Revenue are $52000.0 (Q3 2018), $74000.0 (Q2 2018), and $33948.0 (Q3 2015).